Sahajanand Medical Technologies IPO

Technologically advanced products in segments with high barriers to entry: according to the F&S Report, the company is among a select few Class III (and Class C/D) players in India and globally with a comprehensive portfolio of advanced cardiovascular implants.

Strength: Proven research and development capabilities across product categories and platform technologies, with two R&D facilities in India and Thailand and a team of qualified professionals.

Strength: Leadership in India and key international markets across products, with a nearly 25.00% DES market share in India in FY 2026 according to the F&S Report.

Strength: Deep global sales and marketing presence leading to fast growth in diversified international markets, marketing products in 65 countries (including India) in the three months ended June 30, 2026.

Risk: Material dependence on regulatory approvals and renewals for products and manufacturing; cancellation of registrations could adversely affect business.

Risk: Manufacturing disruptions, quality control issues and under-utilisation of capacity could increase costs and interrupt operations.

Risk: Reliance on a few suppliers and imports; top 10 suppliers contributed 63.61% of purchases in the three months ended June 30, 2026.

Risk: High revenue concentration in Supraflex Cruz, which contributed 37.17% of revenue from operations in Fiscal 2026.

Risk: Price ceilings under NPPA regulation of stents could limit revenues and margins.

Risk: Foreign currency exchange rate fluctuations affect revenues, costs and results; 76.16% of revenue in the three months ended June 30, 2026 came from customers outside India.

Risk: Reliance on distributors, many of whose approvals are held in distributor names, and no long-term agreements with them.

Risk: Intense competition and rapid technological change in the medical device market.